DS
ARCT icon

David Shaw’s Arcturus Therapeutics ARCT Stock Holding History

David Shaw’s Portfolio ARCT Stock Details ARCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.64M Buy
392,358
+140,324
+56% +$1.11M ﹤0.01% 2961
2026
Q1 		$1.95M Buy
252,034
+154,211
+158% +$1.13M ﹤0.01% 2938
2025
Q4 		$600K Buy
97,823
+37,610
+62% +$406K ﹤0.01% 3844
2025
Q3 		$1.11M Buy
60,213
+49,776
+477% +$800K ﹤0.01% 3395
2025
Q2 		$136K Buy
+10,437
New +$123K ﹤0.01% 4093
2024
Q2 		– Sell
-10,355
Closed -$350K – 4472
2024
Q1 		$350K Sell
10,355
-63,440
-86% -$2.25M ﹤0.01% 3661
2023
Q4 		$2.33M Buy
73,795
+29,166
+65% +$693K ﹤0.01% 2548
2023
Q3 		$1.14M Sell
44,629
-57,458
-56% -$1.77M ﹤0.01% 2984
2023
Q2 		$2.93M Buy
+102,087
New +$2.78M ﹤0.01% 2315
2022
Q1 		– Sell
-128,363
Closed -$4.75M – 5503
2021
Q4 		$4.75M Buy
128,363
+32,597
+34% +$1.33M ﹤0.01% 2427
2021
Q3 		$4.58M Sell
95,766
-209,324
-69% -$9.38M ﹤0.01% 2189
2021
Q2 		$10.3M Buy
305,090
+225,152
+282% +$7.62M 0.01% 1473
2021
Q1 		$3.3M Buy
+79,938
New +$4.77M ﹤0.01% 2162
2020
Q3 		– Sell
-5,874
Closed -$275K – 3810
2020
Q2 		$275K Buy
+5,874
New +$202K ﹤0.01% 3658
2017
Q2 		– Sell
-19,745
Closed -$158K – 3352
2017
Q1 		$158K Buy
19,745
+11,993
+155% +$111K ﹤0.01% 3156
2016
Q4 		$114K Buy
7,752
+3,098
+67% +$46.3K ﹤0.01% 3335
2016
Q3 		$80K Sell
4,654
-13,519
-74% -$437K ﹤0.01% 3299
2016
Q2 		$571K Buy
18,173
+946
+5% +$29.8K ﹤0.01% 2732
2016
Q1 		$457K Buy
17,227
+2,931
+21% +$99.2K ﹤0.01% 2827
2015
Q4 		$628K Buy
14,296
+9,935
+228% +$447K ﹤0.01% 2939
2015
Q3 		$184K Buy
4,361
+2,710
+164% +$143K ﹤0.01% 3513
2015
Q2 		$76K Sell
1,651
-5,520
-77% -$253K ﹤0.01% 3668
2015
Q1 		$283K Buy
7,171
+1,150
+19% +$50.6K ﹤0.01% 3326
2014
Q4 		$157K Buy
+6,021
New +$191K ﹤0.01% 3851

Other funds holding ARCT

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

David Shaw's ARCT Position: Q2 2026 in Review

David Shaw increased its Arcturus Therapeutics (ARCT) stake by 56% in Q2 2026, buying an estimated $1.11M and bringing the position to 392,358 shares worth $2.64M. The position accounts for ﹤0.01% of the portfolio, ranked #2961.

David Shaw first reported a position in ARCT in Q4 2014 and has held it in 24 quarters since. The position peaked at $10.3M in Q2 2021. 133 funds tracked by Wall St. Rank hold ARCT as of Q2 2026.

  • David Shaw held 392,358 shares of Arcturus Therapeutics worth $2.64M as of Q2 2026.
  • David Shaw bought 140,324 Arcturus Therapeutics shares in Q2 2026, an estimated $1.11M.
  • Arcturus Therapeutics made up ﹤0.01% of David Shaw's portfolio in Q2 2026, its #2961 holding.
  • David Shaw first reported a position in Arcturus Therapeutics in Q4 2014 and has held it in 24 quarters since.
  • David Shaw's Arcturus Therapeutics position peaked at $10.3M in Q2 2021.
  • 133 funds tracked by Wall St. Rank held Arcturus Therapeutics as of Q2 2026.

Based on D.E. Shaw & Co's 13F filing for Q2 2026, filed 14 Aug 2026.